Latest News & Features
Big Pharma
Depositing a microorganism in a country may be crucial for obtaining a method patent in that jurisdiction, but can come with its pitfalls, says Peter ten Haaft. 4 November 2014
Americas
Jason Rutt considers the impact AstraZeneca’s recent US pay-for-delay case will have on the industry. 3 November 2014
Big Pharma
The current outbreak of Ebola has devastated communities in West Africa. It has also thrown a light on the complex web of IP rights surrounding the possible treatments for this serious and usually fatal virus, as LSIPR discovered. 3 November 2014
Asia-Pacific
Brand owners may use a multitude of approaches to crack down effectively on fake drugs. Andy Leck and Ren Jun Lim discuss the challenges of anti-counterfeiting efforts in Singapore. 3 November 2014
Americas
AstraZeneca has had a tough few years, with a clutch of patent expiries one of the most serious of its problems. So where does it go from here? To find out, LSIPR spoke to the Anglo-Swedish pharmaceutical company’s vice president of business development about the role IP is playing in its plans for future success. 3 November 2014
Americas
Canada’s highest court is set to hear a hotly anticipated dispute pitting generic company Apotex against drug companies Sanofi and Bristol-Myers Squibb (BMS). 3 November 2014
Americas
Biotechnology company Amgen has filed a lawsuit against Sanofi and Regeneron Pharmaceuticals accusing the pair of infringing three patents. 3 November 2014
Europe
Dennis Waller discusses how differing interpretations of the Bolar exemption may affect clinical trials in the UK. 3 November 2014
Americas
Who has legal interest in the grant of sanitary registrations for follow-on biologics? José Trigueros examines a recent case in Mexico that could have far-reaching ramifications. 3 November 2014
Europe
Richard Bassett and Richard Wells look at what EU-based companies must consider in order to comply with the Nagoya Protocol, the regulation aimed at curbing biopiracy. 3 November 2014